Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
NGM Biopharmaceuticals Inc is a biotechnology business based in the US. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. NGM Biopharmaceuticals employs 210 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$19.23|
|52-week range||$14.90 - $32.12|
|50-day moving average||$21.54|
|200-day moving average||$22.28|
|Wall St. target price||$34.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.68|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-0.57%|
|1 month (2021-09-24)||-13.61%|
|3 months (2021-07-26)||-10.01%|
|6 months (2021-04-26)||-31.03%|
|1 year (2020-10-23)||12.79%|
|2 years (2019-10-25)||45.13%|
|3 years (2018-10-22)||N/A|
|5 years (2016-10-22)||N/A|
|Revenue TTM||$81.6 million|
|Gross profit TTM||$-76,604,000|
|Return on assets TTM||-19.81%|
|Return on equity TTM||-36.19%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 788,111 NGM Biopharmaceuticals shares held short by investors – that's known as NGM Biopharmaceuticals's "short interest". This figure is 5.8% up from 745,250 last month.
There are a few different ways that this level of interest in shorting NGM Biopharmaceuticals shares can be evaluated.
NGM Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of NGM Biopharmaceuticals shares currently shorted divided by the average quantity of NGM Biopharmaceuticals shares traded daily (recently around 455555.49132948). NGM Biopharmaceuticals's SIR currently stands at 1.73. In other words for every 100,000 NGM Biopharmaceuticals shares traded daily on the market, roughly 1730 shares are currently held short.
However NGM Biopharmaceuticals's short interest can also be evaluated against the total number of NGM Biopharmaceuticals shares, or, against the total number of tradable NGM Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NGM Biopharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 NGM Biopharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.025% of the tradable shares (for every 100,000 tradable NGM Biopharmaceuticals shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NGM Biopharmaceuticals.
Find out more about how you can short NGM Biopharmaceuticals stock.
We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, NGM Biopharmaceuticals's shares have ranged in value from as little as $14.9 up to $32.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NGM Biopharmaceuticals's is 1.9674. This would suggest that NGM Biopharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NGM Biopharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. ; and a collaboration agreement with Merck & Co. , Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.